ATR-FTIR spectroscopy and CDKN1C gene expression in the prediction of lymph nodes metastases in papillary thyroid carcinoma
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
SILVA, Raissa Monteiro da
PUPIN, Breno
BHATTACHARJEE, Tanmoy Tapobrata
CANEVARI, Renata de Azevedo
Citação
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, v.228, article ID 117693, 7p, 2020
Resumo
Thyroid cancer has become in recent years the most common endocrine malignancy. Among its different types, papillary thyroid carcinoma (PTC) has the highest incidence. PTC is slow growing, but shows a high rate of lymph node metastasis. Tissue biochemical characterization and identification of molecular markers can facilitate stratification of patients into those requiring surgical assessment of lymph nodes and patients for whom this surgical procedure is unnecessary; thus, leading to a more accurate prognosis. To this end, the study aimed to predict lymph node metastasis by Attenuated Total Reflectance Fourier transform infrared (ATR-FTIR) spectroscopy of primary PTC tumors. Another objective of the study was to determine whether CCNA1, CDKN1C, FOS, HSPA5, JUN, KSR1, MAP2K6, MAPK8IP2 and SFN gene expression in primary PTC tumors could be used as predictive markers of lymph node metastasis. Three PTC with lymph node involvement (PTC+), six PTC without lymph node involvement (PTC-), and five normal (N) thyroid tissues were used for FTIR spectroscopy analysis; while 18 PTC+, 17 PTC-, and 6 N samples were used for molecular analysis by real-time quantitative PCR (RT-qPCR). FTIR spectral analysis revealed changes in phosphate groups possibly associated with nucleic acid (1236 cm(-1)), and protein/lipids (1452, 2924, 3821 cm(-1)) in PTC + compared to PTC-, and multivariate analysis could distinguish the two groups. Molecular analysis showed significant increase in CDKN1C gene expression in PTC + compared to PTC-. Being a cell growth regulator, increased CDKN1C provides some supporting evidence to the FTIR spectroscopy based finding of increased nucleic acids in PTC+. Thus, the study suggests the possibility of using FTIR spectroscopy and CDKN1C expression for predicting metastasis using primary tumor alone.
Palavras-chave
Papillary thyroid cancer, Lymph nodes metastases, FTIR, Spectroscopy, Gene expression, Predictive molecular markers, CDKN1C gene
Referências
- Alabbas H, 2016, GLAND SURG, V5, P603, DOI 10.21037/gs.2016.12.06
- Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
- Cha YJ, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1074-7
- Chang YW, 2017, ANN SURG TREAT RES, V92, P117, DOI 10.4174/astr.2017.92.3.117
- Choi KY, 2018, CANCER BIOMARK, V22, P35, DOI 10.3233/CBM-170784
- Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409
- De Crea C, 2017, UPDATES SURG, V69, P205, DOI 10.1007/s13304-017-0468-2
- Depciuch J, 2018, SPECTROCHIM ACTA A, V204, P18, DOI 10.1016/j.saa.2018.06.010
- Eggermann T, 2014, TRENDS MOL MED, V20, P614, DOI 10.1016/j.molmed.2014.09.001
- Engstrom W, 2010, CELL PROLIFERAT, V43, P56, DOI 10.1111/j.1365-2184.2009.00654.x
- Gietka-Czernel M, 2017, MENOPAUSE REV, V16, P33, DOI 10.5114/pm.2017.68588
- Guan HY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3475-2
- Guo K, 2014, INT J CLIN EXP PATHO, V7, P5393
- Hu JX, 2017, CANCER BIOMARK, V18, P87, DOI 10.3233/CBM-161723
- Jia H, 2015, ONCOGENE, V34, P3568, DOI 10.1038/onc.2014.287
- Jung SH, 2016, ONCOTARGET, V7, P69638, DOI 10.18632/oncotarget.11922
- Kim DK, 2015, J LARYNGOL OTOL, V129, P168, DOI 10.1017/S0022215114003351
- Lai SL, 2000, CLIN CANCER RES, V6, P3172
- Lan XB, 2018, GENE, V646, P98, DOI 10.1016/j.gene.2017.12.051
- Landriscina M, 2015, ONCOL LETT, V10, P1875, DOI 10.3892/ol.2015.3386
- Lee J, 2015, J MOL ENDOCRINOL, V54, P115, DOI 10.1530/JME-14-0270
- Lee SH, 2010, OTOLARYNG HEAD NECK, V142, P332, DOI 10.1016/j.otohns.2009.10.050
- Li XM, 2018, ONCOGENE, V37, P2773, DOI 10.1038/s41388-017-0090-2
- Liang WW, 2015, ONCOTARGET, V6, P31780, DOI 10.18632/oncotarget.5566
- Lin MB, 2015, ONCOTARGET, V6, P16774, DOI 10.18632/oncotarget.3736
- Liu Y, 2011, BRIT J SURG, V98, P380, DOI 10.1002/bjs.7330
- Liu YQ, 2009, SPECTROSC SPECT ANAL, V29, P2917, DOI 10.3964/j.issn.1000-0593(2009)11-2917-05
- Maia FFR, 2016, EXP CLIN ENDOCR DIAB, V124, P209, DOI 10.1055/s-0035-1569363
- Manzella L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061325
- Marotta V, 2016, ENDOCR-RELAT CANCER, V23, pR499, DOI 10.1530/ERC-16-0372
- Martinez-Marin D, 2017, VIB SPECTROSC, V91, P77, DOI 10.1016/j.vibspec.2016.09.014
- Matsumoto M, 2000, ANTICANCER RES, V20, P1947
- Movasaghi Z, 2008, APPL SPECTROSC REV, V43, P134, DOI 10.1080/05704920701829043
- Nabhan F, 2017, ENDOCR-RELAT CANCER, V24, pR13, DOI 10.1530/ERC-16-0432
- Park YG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173203
- Pellegriti G, 2013, J CANCER EPIDEMIOL, DOI 10.1155/2013/965212
- Penna GC, 2016, CYTOGENET GENOME RES, V150, P194, DOI 10.1159/000456576
- Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
- Qiu Z, 2018, BIOCHEM BIOPH RES CO, V497, P187, DOI 10.1016/j.bbrc.2018.02.052
- Rossi MN, 2018, FRONT BIOSCI-LANDMRK, V23, P83, DOI 10.2741/4583
- Bertoni APS, 2019, MOL CELL ENDOCRINOL, V479, P54, DOI 10.1016/j.mce.2018.08.013
- Silva R.M., 2018, 22 ENC LAT AM IN CIE
- Wald N, 2016, BBA-MOL BASIS DIS, V1862, P202, DOI 10.1016/j.bbadis.2015.11.008
- Wu M, 2016, INT J CLIN EXP MED, V9, P2351
- Zaballos MA, 2017, J ENDOCRINOL, V235, pR43, DOI 10.1530/JOE-17-0266
- Zhang WT, 2015, CHEM RES CHINESE U, V31, P198, DOI 10.1007/s40242-015-4354-5
- Zhang XQ, 2011, J SURG RES, V171, P650, DOI 10.1016/j.jss.2010.05.031